Hansoh Pharma Ranks in Top Tier of China's Top 100 Most Innovative Pharmaceutical Companies for Eighth Consecutive Year

Source: Hard Code Tech Pie

Recently, E-Drug Manager released the 2026China MedicineTop 100 Innovative Enterprises List: Hansoh Pharma, the parent company of renowned domestic pharmaceutical enterprise Hansoh Pharmaceutical, has once again ranked in the first tier of the list. Since the inception of the list, the company has been among the top echelon of China’s pharmaceutical innovators for eight consecutive years, underscoring its comprehensive full-chain innovation system and sustainable development momentum.

This ranking is built upon a standardized quantitative evaluation model leveraging Clarivate’s authoritative databases. It focuses on three core dimensions—foundations of innovation, innovation processes, and innovation outcomes—and conducts systematic ratings by integrating hard metrics such as patent portfolios, technology diffusion, clinical advancement, and the commercial performance of innovative drugs. Based on full-process R&D data, the ranking comprehensively assesses pharmaceutical companies’ overall innovation capabilities, spanning from upstream technological layout and breakthroughs in clinical technology to industrial implementation. It currently stands as a highly credible and authoritative evaluation system within China’s pharmaceutical industry.

As a leading innovation-driven pharmaceutical enterprise in China, Hansoh Pharma is committed to its mission of "Continuous Innovation to Improve the Quality of Human Life," deeply cultivating major therapeutic areas including oncology, anti-infectives, central nervous system disorders, metabolism, and autoimmune diseases. The company consistently regards R&D innovation as the core driver of corporate development, continuously increasing investment in research and development, with R&D expenditure accounting for 22.4% of total revenue in 2025. Leveraging internationally leading innovative technology platforms and a global R&D team of over 2,300 professionals, the company is simultaneously advancing more than 70 clinical trials for innovative drugs, covering over 40 candidate innovative drug projects. Currently, seven of the company's innovative drugs have been commercialized, and 11 indications have been included in the National Reimbursement Drug List.

Leveraging its robust independent innovation capabilities, Hansoh Pharma is accelerating the implementation of its global strategic layout. The company’s core product, Ameile®, has been successively approved for marketing in the UK and the European Union, becoming the first domestically developed third-generation EGFR-TKI to achieve commercialization overseas. Meanwhile, the company continues to expand its global business development (BD) collaborations, securing three major overseas licensing deals in 2025 with a total transaction value of USD 4.54 billion. Over the past three years, the cumulative scale of its overseas licensing transactions has exceeded USD 9 billion. Benefiting from the sustained sales growth of innovative drugs and the steady progress of global partnerships, the proportion of sales revenue from innovative products to total revenue rose to 82.7% in 2025.

Driven by its long-term dedication and steadfast investment in research and development, Hansoh Pharma has remained in the top tier of the Top 100 Innovative Enterprises for eight consecutive years. This achievement represents strong industry recognition of the company’s innovation capabilities, effectiveness in translating R&D outcomes, and progress in global expansion. Looking ahead, the company will continue to focus onFrontier BiologiesAdvancing pharmaceutical technologies to continuously develop breakthrough innovative therapies, benefiting patients in China and around the world.

Disclaimer: The content presented herein is derived from publicly available information and is published for informational purposes only. It is intended solely as a reference and does not constitute any form of advice.

Special Statement: The above content represents only the views or positions of the author and does not reflect those of Sina Finance Headlines. If you need to contact Sina Finance Headlines regarding the content, copyright, or other issues, please do so within 30 days of the publication of the above content.